[HTML][HTML] A place for biosimilars in the changing multiple sclerosis treatment landscape
Background The treatment paradigm for multiple sclerosis (MS), particularly relapsing-
remitting MS, is heavily reliant on biologic disease-modifying therapies (DMTs). However …
remitting MS, is heavily reliant on biologic disease-modifying therapies (DMTs). However …
Evidence into practice: a national cohort study of NICE-recommended oncological drug therapy utilisation among women diagnosed with invasive breast cancer in …
MR Gannon, D Dodwell, A Aggarwal, MH Park… - British journal of …, 2023 - nature.com
Background Multiple drug treatments are approved for invasive breast cancer (IBC). We
investigated uptake of NICE-recommended oncological drugs and variation by age …
investigated uptake of NICE-recommended oncological drugs and variation by age …
Monoclonal Antibody Biosimilars for Cancer Treatment
Monoclonal antibodies are important cancer medicines. European Medicines Agency (EMA)
approved 40 and Food and Drug Administration (FDA) 48 anticancer monoclonal antibody …
approved 40 and Food and Drug Administration (FDA) 48 anticancer monoclonal antibody …
Real-world clinical scenarios during introduction of trastuzumab biosimilar for HER2-positive breast cancer in the European Union
L Wyrwicz, CA Rodríguez Sánchez… - Future …, 2024 - Taylor & Francis
Aim: Trastuzumab-anns is an intravenously administered biosimilar to trastuzumab
approved by the EMA and US FDA for treatment of HER2+ early and metastatic breast …
approved by the EMA and US FDA for treatment of HER2+ early and metastatic breast …
Drug utilization research in the area of cancer drugs
T Mueller, M Hoffmann - Drug Utilization Research: Methods …, 2024 - Wiley Online Library
The world‐wide impact of cancer on life expectancy, quality of life, and need for healthcare
interventions together explain the research interest and rapid development of new …
interventions together explain the research interest and rapid development of new …
Safety evaluation of the trastuzumab biosimilar in Iranian women with HER2-positive breast cancer undergoing adjuvant chemotherapy: a post-marketing surveillance
F Zahedi, A Jafari, B Nasiri Motlagh… - Expert Opinion on …, 2024 - Taylor & Francis
Background Trastuzumab is a humanized monoclonal antibody against the human
epidermal growth factor receptor 2 (HER2). This post-marketing surveillance evaluates the …
epidermal growth factor receptor 2 (HER2). This post-marketing surveillance evaluates the …
A Comprehensive Review on the State of the Art of Breast Cancers in Italy
D Iacopetta, J Ceramella, A Catalano… - Current Medicinal …, 2024 - benthamdirect.com
Breast cancer (BC) currently represents one of the most prevalent cancers among women
worldwide and the leading cause of cancer death among women, also negatively affecting …
worldwide and the leading cause of cancer death among women, also negatively affecting …
Biosimilar in Cervical Cancer
Cervical Cancer is a serious health concern possessing a serious health problem in women.
This chapter provides a comprehensive overview of the role of biosimilars in Cervical …
This chapter provides a comprehensive overview of the role of biosimilars in Cervical …
Assessing the Uptake of Biosimilar Insulin Glargine Among Physicians for the Treatment of Diabetes in South Africa
E Pillay - 2024 - search.proquest.com
Abstract In South Africa, diabetes is a serious problem where 1 in 9 adults has diabetes,
making it the country with the highest diabetes prevalence on the African continent. Even …
making it the country with the highest diabetes prevalence on the African continent. Even …
Bioslični lijekovi kao terapijska alternativa referentnom biološkom lijeku trastuzumabu
Ž Modrić - 2024 - zir.nsk.hr
Sažetak CILJ ISTRAŽIVANJA: Cilj ovog specijalističkog rada je dati pregled trenutno
dostupnih i registriranih trastuzumabu biosličnih lijekova u Europskoj uniji, uz poseban osvrt …
dostupnih i registriranih trastuzumabu biosličnih lijekova u Europskoj uniji, uz poseban osvrt …